Stockscreener 앱 받기
14.59
1.08%
-0.16
시간 외 거래:
14.55
-0.04
-0.27%
전일 마감가:
$14.75
열려 있는:
$14.75
하루 거래량:
14.34M
Relative Volume:
1.41
시가총액:
$16.99B
수익:
$14.29B
순이익/손실:
$-3.51B
주가수익비율:
-4.9286
EPS:
-2.9603
순현금흐름:
$1.85B
1주 성능:
-0.61%
1개월 성능:
+9.21%
6개월 성능:
+40.97%
1년 성능:
+81.69%
1일 변동 폭
$14.42
$14.82
1주일 범위
$14.36
$15.21
52주 변동 폭
$7.935
$16.47
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
14.59 | 16.99B | 14.29B | -3.51B | 1.85B | -2.9603 |
TAK
Takeda Pharmaceutical Co Adr
|
16.63 | 52.54B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.87 | 49.15B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.58 | 42.62B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 35.68B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
567.16 | 24.86B | 3.18B | 1.33B | 1.04B | 27.90 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 업그레이드 | UBS | Neutral → Buy |
| 2026-01-16 | 업그레이드 | Argus | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Viatris Inc. stock rises Friday, outperforms market - MSN
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Discipline and Rules-Based Execution in VTRS Response - Stock Traders Daily
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
FDA Issues Nationwide Recall of ‘Extended Release’ Xanax for Anxiety - Healthline
Taking Xanax XR? FDA Recalls Batch Over Effectiveness Concerns - AOL.com
Viatris' Q1 2026 Earnings: What to Expect - Yahoo Finance
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Is Viatris Inc (VTRS) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
Viatris Inc. (VTRS) Stock Analysis: Navigating Challenges With A 7.10% Potential Upside - DirectorsTalk Interviews
Transdermal Skin Patches Market 2026- 2033 Overview: Share, - openPR.com
FDA Lists Xanax Recall. Here’s What You Need To Know - Forbes
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know - Yahoo Finance
Is Viatris Inc (VTRS) Overvalued After 4.7% Rally? GF Value Says - GuruFocus
Xanax recalled nationwide due to potential issue with quality, efficacy - The National News Desk
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Popular anxiety medication recalled nationwide after FDA warning - NewsNation
Xanax XR recalled after discovery that tablets may fail to release medication properly - Fox Business
Viatris (VTRS) CCO nets 107,135 shares after RSU and DEU vesting - Stock Titan
Why the Xanax recall may not impact your prescription - The Hill
Popular Prescription Medication Xanax Is Being Recalled Nationwide - AOL.com
Xanax from West Virginia-based company recalled nationwide. What you need to know - Los Angeles Times
Xanax bottles recalled nationwide over dissolution issues - WCVB
Popular anxiety Xanax drug recalled nationwide: How to check if your prescription is included - nypost.com
Xanax, popular anxiety medication, recalled: What to know - FOX 13 Tampa Bay
Popular anxiety drug Xanax recalled nationwide: What to know - NBC 5 Chicago
Bottles of Xanax, a popular anxiety drug, recalled nationwide. Here’s why - KFOR.com
Popular anxiety prescription recalled nationwide - WJHL
Bottles of Xanax recalled nationwide. Here’s why - CBS 42
Viatris Ophthalmology Data At ASCRS Puts Valuation And Dividend In Focus - Sahm
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 - Lelezard
FDA Recalls and Warnings: Potentially Contaminated Cough Drops and Eye Drops, Subpotent Thyroid Medications & More - MedShadow Foundation
Behavioral Patterns of VTRS and Institutional Flows - Stock Traders Daily
Barclays Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Viatris Announces Multiple Data Presentations at ASCRS Annual Meeting - National Today
Night Vision Disturbances Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Opus Genetics, Viatris, Nevakar, Vyluma, Pfizer, Allergan, AbbVie - Barchart.com
Xanax Has Been Recalled Nationwide, According to a New FDA Report - The Healthy @Reader's Digest
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting - PR Newswire
Viatris Announces Launch of Breyna™ (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People With Asthma and Chronic Obstructive Pulmonary Disease, in Partnership With Kind - CSRwire
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Momentum Shift: Is Viatris Inc impacted by rising ratesWeekly Loss Report & Weekly High Momentum Picks - baoquankhu1.vn
Truist Financial Maintains Viatris(VTRS.US) With Buy Rating - Moomoo
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.90%
0.66%
자본화:
|
볼륨(24시간):